MFS New Discovery’s strengths remain intact, and it retains its Above Average People and Process Pillar ratings.
MFS New Discovery Fund Class R2 MNDRX
- NAV / 1-Day Return 25.97 / −2.11 %
- Total Assets 2.1B
-
Adj. Expense Ratio
1.460%
- Expense Ratio 1.520%
- Distribution Fee Level Above Average
- Share Class Type Retirement, Medium
- Category Small Growth
- Investment Style Small Growth
- Min. Initial Investment 0
- Status Limited
- TTM Yield 0.00
- Turnover 68%
USD | NAV as of Jun 11, 2026 | 1-Day Return as of Jun 11, 2026, 12:11 AM GMT+0
Morningstar’s Analysis MNDRX
Will MNDRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the MNDRX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of MNDRX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 19.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Currency Cash CASH_USD | 4.61 | 98M | Cash and Equivalents |
Advanced Energy Industries Inc | 2.54 | 54M | Industrials |
TTM Technologies Inc | 2.09 | 44M | Technology |
MACOM Technology Solutions Holdings Inc | 2.04 | 43M | Technology |
Legence Corp Ordinary Shares - Class A | 1.97 | 42M | Industrials |
Element Solutions Inc | 1.96 | 41M | Basic Materials |
Littelfuse Inc | 1.92 | 41M | Technology |
CACI International Inc Class A | 1.92 | 41M | Technology |
Ligand Pharmaceuticals Inc | 1.91 | 40M | Healthcare |
Bio-Techne Corp | 1.77 | 37M | Healthcare |
United States